WuXi AppTec Seals Partnership Agreement With Qiagen
Under the terms of agreement, Qiagen is expected to provide a complete portfolio of instrumentation, training, and consumables and WuXi AppTec will provide laboratory facilities and staff to
Teva Pharmaceuticals International and Polpharma Biologics have signed a global licensing agreement for a proposed biosimilar to Ocrevus (ocrelizumab) to treat multiple sclerosis (MS).